Palbocib 125mg Capsule

The human body reacts differently to Palbocib 125mg capsules. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Palbocib 125mg capsules are mentioned below: 

• Fatigue
• Hair loss
• Rash
• Vomiting
• Diarrhea
• Nausea
• Low appetite,
• Infection
• Inflammation of the mouth
• Anemia 
• Weakness
• Fever
• Decreased white blood cell count
  
• Neutropenia
• leucopenia
• Alopecia
  

• Take the dose of Palbocib 125mg capsules as per your healthcare provider’s prescription.
• Palbocib 125mg capsules should be taken with food.
• You should not break, crush, or chew the medicine; it should be swallowed as a whole.
  
• Routine blood tests are done to monitor how Palbociclib affects your blood cells, including white cells, red cells, and platelets.
  

• Palbociclib 125mg capsules, an anticancer medicine, work by inhibiting cyclin-dependent kinase 4 and 6; as a result, cell growth ceases or stops, arresting the cancer cell cycle.
• Cyclin-dependent kinase 4 and 6 (chemical messengers) play an essential role in downstream signaling pathways, which lead to the proliferation of cells.
• It also disrupts the cell cycle by targeting estrogen (hormone) receptor-positive breast cancer cells.
  

• Fry DW, Harvey PJ, Keller PR et al. (2023). Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 2004; 3: 1427–38. https://pubmed.ncbi.nlm.nih.gov/15542782/
  
• Marzec M, Kasprzycka M, Lai R et al. (2025). Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood 2006; 108: 1744–50. https://pubmed.ncbi.nlm.nih.gov/16690963/
  
  
• Finn RS, Dering J, Conklin D et al. (2024). PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11: R77. https://pubmed.ncbi.nlm.nih.gov/19874578/
  
  
• Finn RS, Crown JP, Lang I et al. (2023). The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol . 16: 25–35. https://pubmed.ncbi.nlm.nih.gov/25524798/
  
• Xiao H, Sooryanarayana V, Sarah A. A, Brooke B. B, Shuko H, Shi W, Gene P. S, Katia K, Ceren Y. (2023). A Genomic Alteration in GATA3 Affects Treatment Responses With a CDK4/6 Inhibitor Collaborating With p18INK4C Expression in Advanced Breast Carcinoma, Modern Pathology, 38, 12, (100841). https://pubmed.ncbi.nlm.nih.gov/40680849/
  
• Karasic TB, O'Hara MH, Teitelbaum UR, Damjanov N, Giantonio BJ, d'Entremont TS, Gallagher M, Zhang PJ, O'Dwyer PJ. (2024). Phase II Trial of Palbociclib in Patients with Advanced Esophageal or Gastric Cancer. Oncologist. 25(12):e1864-e1868. https://pubmed.ncbi.nlm.nih.gov/32692450/​